Objective Despite the efficacy of clinical treatments (eg, adjuvant hormonal therapy) for breast cancer survivors (BCS), nonadherence rates remain high, increasing the risk of recurrence and mortality. The current study tested a theoretical model of medical nonadherence that proposes depression to be the most proximal predictor of medical nonadherence among BCS.
| INTRODUCTION
In 2010, the costs of healthcare, in the USA, surpassed $2.7 trillion, with an estimated $100 billion to $300 billion of the costs attributed to medication nonadherence. 1 Medical nonadherence, or patients' reluctance to follow a prescribed treatment plan, 2 has significant effects on health, estimated to cause up to 10% of hospitalizations as well as an increase in morbidity and mortality. [3] [4] [5] Conversely, among the general population, patients who adhere to their treatment and medication regimes are more likely to experience a variety of favorable outcomes. 4, 6 Despite numerous interventions designed to improve patient adherence, nonadherence is a persistent problem. 7, 8 Because treatments significantly reduce mortality rates for breast cancer survivors (BCS), 9 it is important to maximize risk-reducing behaviors and quality of life (QOL). 10, 11 Critical to survivorship care is adjuvant hormonal therapy that significantly reduces the prevalence and recurrence of invasive breast cancer (BC). 12, 13 Consistent with these findings, BCS who adhere to their treatment plan are less likely to experience recurrence and have a greater chance of survival. 14, 15 Notwithstanding the efficacy of these treatments, nonadherence rates range from 25% to 50%, 10 substantially increasing the risk of recurrence and mortality among BCS. 14, 15 The purpose of the current investigation is to understand the factors that predict nonadherence to medication regimens, particularly among BCS.
Although a wealth of research has elucidated the risk factors associated with nonadherence for BCS, 10, 16 few studies have examined the 
The data used to test the model of Fann et al were derived from 1 measurement period of a larger longitudinal study of female BCS. Survivors were recruited from 9 radiation clinics in Missouri. Eligible patients were (1) female, (2) 18 years of age or older, (3) undergoing radiation treatment at one of the participating clinic sites, and (4) English-speaking. Of the participants, 79% had completed chemotherapy treatment by the second assessment, 15% did not have chemotherapy, and for 6%, this information was not reported. Eligible BCS were mailed surveys 12 months after the end of radiation treatment.
| Participants
Of the 203 BCS that completed this survey, 133 reported being prescribed with antiestrogen or estrogen-inhibiting medication (eg, aromatase, novladex, and tamoxifen) and completed the measure of MA; these 133 BCS comprise the sample for the current investigation.
Those who were included in the current sample differed significantly on only the cognitive symptoms measure; those in the current sample reported somewhat less severe cognitive symptoms, M = 2.97, than the remaining, 3.41, t(190) = −1.99, P < .05. No other significant differences were found for the primary and demographic variables (all t values < 1.34, all χ 2 < 9.46, and all Ps > .05).
Participants were asked about their total household annual income, the categories were organized in increments of $10 000 from less than $15 000 to $115 000 or more (eg, less than $15 000, were missing). One hundred twenty-four participants identified as White (93.2%), 3.8% identified as African-American, Asian-American, American-Indian, or other (3% were missing). The majority of participants were married or cohabitating (69.2%), 11.3% were divorced, 4.5% were single, 11.3% were widowed, and 2.3% reported "other"
(1.5% were missing). The average age was 68.4 years (SD = 12.74 years). The scale has been used, often, in studies of cancer survivors 27 and assessed the regularity of depressive symptoms, using a 4-point scale 
| Profile of Mood States scale
The 35-item Profile of Mood States 29 scale was used to measure mood disturbance because of its wide use in studies of cancer patients. 26 The
Profile of Mood States questionnaire assesses 6 mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion in a 5-point format (0, "Not at all"; 4, "Extremely"). Mood disturbance scores were computed by adding the totals of 5 negative-mood subscales and subtracting the vigor total (α range = .83-.94) Higher scores indicated greater mood disturbance.
| Medication Adherence scale
Participants were asked if they were taking an antiestrogen medication (eg, aromatase, novladex, and tamoxifen) as part of your BC treatment (yes or no). We used Morisky, Green, and Levine's 30 Medication
Adherence scale because of its feasibility, reliability, and validity for measuring adherence. Four items assessed whether participants adhered to the medications used as a part of their BC treatment. Participants responded using a 5-point scale (1, "Very often"; 5, "Never"); a higher average score represented greater adherence (α = .71).
| Physical and cognitive symptoms
The survey included 20 symptoms based on their appropriateness for the sample. 31, 32 Participants were asked to report the severity of these symptoms during the last month. The scale was a 7-point scale (1 = "Not at all" to 7 = "Severe"). Seventeen of the symptoms were physical in nature (eg, chest wall pain and swelling of the arm). The average of these items was used as an indicator of severity of physical symptoms (α = .78). Three were cognitive symptoms (eg, forgetfulness and difficulty in concentrating). The average of these items were the indicator of severity of cognitive symptoms (α = .82).
| Psychosocial variables
Participants' perceptions of social support from 5 sources (ie, spouse/ partner, female family members, other family members, friends, and community members) were assessed. 33 We adopted this measure of social support because it was developed for use with BCS and it allowed participants to assess social support from a variety of sources.
For each source, 4 items assessed level of social support (eg, How much do you feel you can count on your [source] to perform daily chores?). A 6-point scale was used (1 = "Not at all", 6 = "A lot"); an average score was calculated across all sources (α = .78). The measure of internal health ILC, 34 which is 1 subscale in the Multidimensional
Health Locus of Control assessment and is used with patient populations. 27 It is comprised of 6 items (eg, My physical well-being depends on how well I take care of myself.), with a scale ranging from 1 (strongly disagree) to 6 (strongly agree). The reliability of this scale was unacceptably low (α = .34).
| RESULTS
We adopted Baron and Kenny's 31 analytical method to test mediation, using regression analyses. First, we conducted correlational analyses to determine if the distal predictor variables were associated with depres- 
| Correlational analyses
As shown in Table 1 As explained in the previous section, the first step of the mediational analyses was to determine whether cognitive functioning, physical functioning, and social support uniquely predicted MA in a single regression model. 31 Consistent with the hypotheses, the results showed that cognitive functioning, β = −.20, t(127) = −2.06, P < .05, and physical functioning, β = −.22, t(127) = −2.23, P < .05, uniquely predicted lower levels of MA, and social support uniquely predicted greater adherence β = .18, t(127) = 2.11, P < .05. The next step was to determine whether these 3 variables uniquely predicted the proposed mediator. In a single regression analysis, cognitive symptoms, β = .33, t(127) = 4.01, P < .001, and physical symptoms, β = .22, t(127) = 2.72, P < .01, uniquely predicted higher levels of depressive symptoms, and social support uniquely predicted lower depression, β = −.14, t(127) = −2.05, P < .05.
The final step in the mediational analyses was to determine whether the association between cognitive and physical symptoms and MA was explained by depressive symptoms. As shown in 
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Replicating these findings, mood disturbance was also predicted by cognitive symptoms, β = .48, t(126) = 6.10, P < .001; physical symptoms, β = .17, t(126) = 2.13, P < .05; and social support, β = −.13, 
| Implications
The model of Fann et al 17 
ENDNOTES
1 We did not have a candidate measure that could be used as an operationalization of family cohesion, so we were unable to test predictions regarding family cohesion.
2 Because 17 of the 133 BCS refrained from reporting their household income, these missing data were imputed with the mean score. Relationship status was recoded such that those who were married or cohabitating were coded as 1 and all others were coded as 2.
